MAY 30, 2018 12:00 PM PDT

High Throughput Screening Robotics within the UK Centre for Drug Discovery

Presented at: Lab Automation 2018
C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Director High Throughput Screening, AstraZeneca
    Biography
      Mark Wigglesworth joined AstraZeneca in Sept 2012 to lead the newly formed Global High Throughput Screening Centre. His screening experience was gained at SmithKline Beecham and GlaxoSmithKline where he worked extensively in G-Protein coupled receptor (GPCR) drug discovery initiating and leading a number of projects to deliver lead molecules to drug discovery programmes. Mark has led groups of scientists responsible for delivery of structure activity relationship data to iterative chemistry programmes as well as working within Compound Management. Mark has worked collaboratively with several academic groups and organisations such as MRC-T, has contributed to numerous publications in the field of GPCR pharmacology and Compound Management including editing a book describing the Management of Biological and Chemical Samples for Screening Applications. In his current role he leads a team of more than 20 scientists dedicated to identifying novel chemical starting points for drug discovery programmes.

    Abstract

    AstraZeneca has an ambition to create a porous organisation, seamlessly collaborating with external partners. This desire has led to the establishment of the AstraZeneca-MRC UK Centre for Lead Discovery, ultimately located in the future R&D centre in Cambridge, UK. 

    This new global screening centre encompassing AstraZeneca, Medical Research Council, Cancer Research UK and additional scientific partners has created the unique opportunity to completely re-develop our screening infrastructure and its capabilities, resulting in the concept of our next generation of HTS automation to deliver the varied capacity and assays formats across this partnership. This presentation will describe the generation, use and support for this new generation of HTS screening. 
     

    Learning Objectives: 

    1. To understand the complexity of a High Throughput Screening laboratory
    2. How collaborations can drive further success


    Show Resources
    You May Also Like
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    FEB 26, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    OCT 30, 2019 7:00 AM PDT
    C.E. CREDITS
    OCT 30, 2019 7:00 AM PDT
    DATE: October 30, 2019TIME: 7:00am PDTJoin us for a webinar to learn how to apply single cell methods to study cancer. Dr. William Greenleaf, Associate Professor from Stanford Universit...
    MAR 03, 2020 9:00 AM PST
    C.E. CREDITS
    MAR 03, 2020 9:00 AM PST
    DATE: March 3, 2020 TIME: 9:00am PT, 12:00pm ET Despite the advances of new drugs and the lowering of carbapenem breakpoints to enhance detection of CRE, there should be no complacency about...
    OCT 29, 2019 7:00 AM PDT
    C.E. CREDITS
    OCT 29, 2019 7:00 AM PDT
    DATE: October 29, 2019TIME: 7:00am PDT3D cell culture systems have recently emerged as tools for reproducing the cellular environment and the organization of tissues/organs, where cel...
    Loading Comments...
    Show Resources